Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
14.51
USDSponsored
+0.01
+0.07%
Sep 18, 15:59 UTC -4
Closed
After-Market
14.55
+0.04
+0.25%
RARE Earnings Reports
Positive Surprise Ratio
RARE beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$186.59M
/-$1.01
Implied change from Q2 26 (Revenue/ EPS)
-12.81%
/+12.22%
Implied change from Q3 25 (Revenue/ EPS)
+16.67%
/-44.20%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On Aug 04, 2026, RARE reported earnings of -0.90 USD per share (EPS) for Q2 26, beating the estimate of -1.23 USD, resulting in a 27.39% surprise. Revenue reached 214.00 million, compared to an expected 186.35 million, with a 14.84% difference. The market reacted with a -3.41% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 14 analysts forecast an EPS of -1.01 USD, with revenue projected to reach 186.59 million USD, implying an increase of 12.22% EPS, and decrease of -12.81% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ultragenyx Pharmaceutical Inc. reported EPS of -$0.90, beating estimates by 27.39%, and revenue of $214.00M, 14.84% above expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q2 2026 earnings?
The stock price moved down -3.41%, changed from $25.81 before the earnings release to $24.93 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 14
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.01 and revenue of $186.59M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.